Crosstalk between wnt signaling and RNA processing in colorectal cancer

Journal of Cancer

Volumn 4, Issue 2, 2013, Pages 96-103

  Bordonaro, Michael ^a  

^a Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

Author keywords

Butyrate; Colon cancer; Polyadenylation; RNA processing; Splicing; Wnt activity

Indexed keywords

BUTYRIC ACID; CYCLOOXYGENASE 2; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROTEIN C JUN; TCF4 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ARTICLE; CARCINOGENESIS; COLON CARCINOGENESIS; COLORECTAL CANCER; DIETARY FIBER; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; INTRON; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; NONHUMAN; POLYADENYLATION; RNA CLEAVAGE; RNA METABOLISM; RNA PROCESSING; RNA STABILITY; SIGNAL PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84883041381     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5470     Document Type: Article

References (57)

1. Bingham S. Mechanisms and experimental evidence relating dietary fibre and starch to protection against large bowel cancer. Proc Nutr Soc. 1990; 49: 153-171.
2. Boffa LC, Lupton JR, Mariani MR, Ceppi M, Newmark HL, Scalmati A, Lipkin M. Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res. 1992; 52: 5906-5912.
3. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res. 1994; 54: 3288-3294.
4. Medina V, Young GP, Edmonds B, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and another inhibitor of histone deacetylase: dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997; 57: 3697-3707.
5. Bordonaro M, Mariadason JM, Aslam F, Heerdt BG, Augenlicht LH. Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the beta-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Cell Growth Differ. 1999; 10: 713-720.
6. Lazarova DL, Bordonaro M, Carbone R, Sartorelli AC. Linear relationship between WNT activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate. Internat J Cancer 2004; 110:523-531.
7. Bordonaro M, Lazarova DL, Sartorelli AC. The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res. 2007; 313:1652-1666.
8. Korinek V, Barker N, Morin PJ, Van Wichen D, De Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta- catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275:1784-1787.
9. Lee HK, Choi YS, Park YA, Jeong S. Modulation of oncogenic transcription and alternative splicing by β-catenin and an RNA aptamer in colon cancer cells. Cancer Res. 2006; 66: 10560-10566.
10. Lee HK, Kwak HY, Hur J, Kim IA., Yang JS, Park MW, Yu J, Jeong S. Beta-catenin regulates multiple steps of RNA metabolism as revealed by the RNA aptamer in colon cancer cells. Cancer Res.2007; 67: 93150-9321.
11. Krupitza G, Harant H, Dittrich E, Szekeres T, Huber H, Dittrich C. Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells. Carcinogenesis 1995; 16: 1199-1205.
12. Chang J-G, Hsieh-Li H-M, Jong Y-J, Wang NM, Tsai C-H, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci. USA 2001; 98: 9808-9813.
13. Nakagawa T, Nelkin BD, Baylin SB, de Bustros A. Transcriptional and posttranscriptional modulation of calcitonin gene expression by sodium n-butyrate in cultured human medullary thyroid carcinoma. Cancer Res. 1988; 48: 2096-2100.
14. Corbo C, Orru S, Gemei M, Noto RD, Mirabelli P, Imperlini E, Ruoppolo M, Vecchio LD, Salvatore F. Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and up-regulation of SRp20 that is potentially involved in tumorigenicity. Proteomics 2012; 12: 2045-2059.
15. Nasim MT, Chowdhury HM, Eperon IC. A double reporter assay for detecting changes in the ratio of spliced and unspliced mRNA in mammalian cells. Nucl Acids Res. 2002; 30: e109.
16. Cuperlovic-Cuif M, Belacel N, Culf AS, Ouellette RJ. Microarray analysis of alternative splicing. OMICS: A Journal of Integrative Biology 2006; 10: 344-357.
17. Hughes TR, Hiley SL, Saltzman AL, Babak T, Blencowe BJ. Microarray analysis of RNA processing and modification. Methods Enzymol. 2006; 410: 300-316.
18. McKee AE, Silver PA. Systems perspectives on mRNA processing. Cell Res. 2007; 17: 581-590.
19. Sahota AP, Dhoot GK. A novel SULF1 splice variant inhibits Wnt signaling but enhances angiogenesis opposing SULF1 activity. Expt Cell Res. 2009; 315:2752-2764.
20. Li Q, Liu X., Zhang M, Ye G, Qiao Q, Ling Y, Wu Y, Zhang Y, Yu L. Characterization of a novel human CDK5 splicing variant that inhibits Wnt/beta-catenin signaling. Mol Biol Rep. 2010; 37: 2415-2421.
21. Sharma S, Lichtenstein A. Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood 2009; 114: 4179-4185.
22. Goncalves V, Matos P, Jordan P. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Genet. 2009; 18: 3696-3707.
23. Prokunina-Olsson L, Welch C, Hansson O, Adhikari N, Scott L, Usher N, Tong M, Sprau A, Swift A, Bonnycastle L, Erdos M, He Z, Saxena R, Harmon B, Kotova O, Hoffman E, Altshuler D, Groop L, Boehnke M., Collins F, Hall JL. Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet. 2009; 18: 3795-3804.
24. Esufali S, Charames GS, Bapat B. Suppression of nuclear Wnt signaling leads to stabilization of Rac1 isoforms. FEBS Lett. 2007; 581: 4850-4856.
25. Esufali S, Charames GS, Pethe VV, Buongiorno P, Bapat B. Activation of tumor-specific splice variant Rac1b by disheveled promotes canonical Wnt signaling and decreased adhesion of colorectal cancer cells. Cancer Res. 2007; 67: 2469-2479.
26. Zerbe LK, Pino I, Pio R, Cosper PF, Dwyer-Nield LD, Meyer AM, Port JD, Montuenga LM, Malkinson AM. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre-mRNA processing. Mol Carcinogen. 2004; 41:187-196.
27. Sato S, Idogawa M, Honda K, Fujii G, Kawashima H, Takekuma K, Hoshika A, Hirohashi S, Yamada T. β-catenin interacts with FUS proto- oncogene product and regulates pre-mRNA splicing. Gastroenter. 2005; 129: 1225-1236.
28. Sakharkar MK, Kangueane P, Petrov DA, Kolaska AS, Subbiah S. SEGE: a database on 'intronless/single exonic' genes from eukaryotes. Bioinformatics 2002; 18: 1266-1267.
29. Agarwal SM, Srivistava PK. Human intronless disease genes are slowly evolving. BMB Reports 2009; 42: 356-360.
30. Agarwal SM. Evolutionary rate variation in eukaryotic lineage specific human intronless proteins. Biochem Biophys Res Commun. 2005; 337: 1192-1197.
31. Agarwal SM, Gupta J. Comparative analysis of human intronless proteins. Biochem Biophys Tes Commun. 2005; 331: 512-519.
32. Lopez-Bigas N, Ouzounis CA. Genome-wide identification of genes likely to be involved in human genetic disease. Nucl Acids Res. 2004; 32: 3108-3114.
33. Hill AE, Sorscher EJ. The non-random distribution of intronless genes across molecular function categories. FEBS Lett. 2006; 580:4303-4305.
34. Jeffares DC, Penkett CJ, Bahler J. Rapidly regulated genes are intron poor. Trends Genet. 2008; 24: 375-378.
35. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 1987; 238: 1386-1392.
36. Rahmsdorf HJ. Jun: transcription factor and oncoprotein. J Mol Med. 1996; 74: 725-747.
37. Ashida R, Tominaga K, Sasaki E, Watanabe T, Fujiwara Y, Oshitani N, Higuchi K, Mitsuyama S, Iwao H. Arakawa T. AP-1 and colorectal cancer. Inflammopharm. 2005; 13: 113-125.
38. Suto R, Tominaga K, Mizuguchi H, Sasaki E, Higuchi K, Kim S, Iwao H, Arakawa T. Dominant-negative mutant of c-jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther. 2004; 11: 187-193.
39. Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B, Behrens A. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J. 2009; 28: 1843-1854.
40. Yochum GS, Cleland R, Goodman RH. A genome-wide screen for beta- catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol. 2008; 28: 7368-7379.
41. Lee CW, Lee SH, Lee SW, Ban JO, Lee SY, Yoo HS, Jung JK, Moon DC, Oh KW, Hung JT. 2-hydroxycinnamaldehyde inhibits SW620 colon cancer cell growth through AP-1 inactivation. J Pharmacol Sci. 2007; 104: 19-28.
42. Guang S, Mertz JE. Pre-mRNA processing enhancer (PPE) elements from intronless genes play additional roles in mRNA biogenesis than do ones from intron-containing genes. Nucl Acids Res. 2005; 33: 2215-2226.
43. Narjano JR, Mellstrom B, Auwerx J, Mollinedo F, Sassone-Corsi P. Unusual c-fos induction upon chromaffin PC12 differentiation by sodium butyrate: loss of fos autoregulatory function. Nucl Acids Res. 1990; 18: 3605-3610.
44. Velasquez OC, Zhou D, Seto RW, Jabbar A, Choi J, Lederer HM, Rombeau JL. In vivo crypt surface hyperproliferation is decreased by butyrate and increased by deoxycholate in normal rat colon: associated in vivo effects on c-fos and c-jun expression. J Parent Ent Nutr. 1996; 20: 4243-4250.
45. Rabizadeh E, Shaklai M, Nudelman A, Eisenbach L, Rephaeli A. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett. 1993; 328: 225-229.
46. Singh P, Alley TL, Wright SM, Kamdar S, Schott W, Wilpan RY, Mills KD, Graber JH. Global changes in processing of mRNA 3' untranslated regions characterize clinically distinct cancer subtypes. Cancer Res. 2009; 69: 9422-9430.
47. Mayr C, Bartel DP. Widespread shortening of 3' UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009; 138:673-684.
48. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 1995; 55: 5226-5229.
49. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995; 55: 3537-3542.
50. Locke JM, Da Silva Xavier G, Rutter GA, Harries LW. An alternative polyadenylation signal in TCF7L2 generates isoforms that inhibit T cell factor/lymphoid enhancer factor (TCF/LEF)-dependent target genes. Diabetologia 2011; 54: 3078-3082.
51. Lee HK., Jeong S. β-catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3' UTR. Nucl Acids Res. 2006; 34: 5705-5714.
52. Hall-Pogar T, Zhang H, Tian B, Lutz CS. Alternative polyadenylation of cyclooxygenase-2. Nucl Acids Res. 2005; 33: 2565-2579.
53. Keene JD. The global dynamics of RNA stability orchestrates responses to cellular activation. BMC Biol. 2010; 8:95.
54. Keene JD. Minireview: global regulation and dynamics of ribonucleic acid. Endocrinology 2010; 151: 1391-1397.
55. Mukherjee N, Cordoran DL, Nusbaum JD, Reid DW, Georgiev S, Hafner M, Ascano Jr. M, Tuschl T, Ohler U, Keene JD. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol Cell 2011; 43:327-339.
56. Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, Gorospe M, Keene J, Levenson AS, Gartenhaus RB. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 2008; 27: 6151-6163.
57. Kim I, Kwak H, Lee HK, Hyun S, Jeong S. β-catenin recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3'-UTR and interacts with HuR in colon cancer cells. Nucl Acids Res. 2012; 40: 6863-6872.